Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses.

ABSTRACT: COVID-19, first reported in late 2019, is an ongoing pandemic that has been causing devastation across the globe. Although there are multiple vaccines that can prevent severe symptoms, effective COVID-19 therapeutics are still of importance. Using our proprietary in silico engine, we screened more than 22,000 unique compounds represented by over half a million gene expression profiles to uncover compounds that can be repurposed for SARS-CoV-2 and other coronaviruses in a timely and cost-efficient manner. We then tested 13 compounds in vitro and found three with potency against SARS-CoV-2 with reasonable cytotoxicity. Bortezomib and homoharringtonine are some of the most promising hits with IC₅₀ of 1.39 μM and 0.16 μM, respectively for SARS-CoV-2. Tanespimycin and homoharringtoni

SUBMITTER: Shen Z 

PROVIDER: S-EPMC9637228 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature